

Chiara Riganti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2292570/publications.pdf>

Version: 2024-02-01

226
papers

10,119
citations

36303

51
h-index

56724

83
g-index

233
all docs

233
docs citations

233
times ranked

15854
citing authors

#	ARTICLE	IF	CITATIONS
1	Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein. <i>Pharmacological Research</i> , 2022, 175, 105975.	7.1	14
2	Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro. <i>Bioorganic Chemistry</i> , 2022, 119, 105514.	4.1	10
3	Targeted Self-Emulsifying Drug Delivery Systems to Restore Docetaxel Sensitivity in Resistant Tumors. <i>Pharmaceutics</i> , 2022, 14, 292.	4.5	7
4	Sdox, a H ₂ S releasing anthracycline, with a safer profile than doxorubicin toward vasculature. <i>Vascular Pharmacology</i> , 2022, 143, 106969.	2.1	4
5	Inhibition of Heme Export and/or Heme Synthesis Potentiates Metformin Anti-Proliferative Effect on Cancer Cell Lines. <i>Cancers</i> , 2022, 14, 1230.	3.7	5
6	SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 75.	8.6	7
7	A Biomonitoring Pilot Study in Workers from a Paints Production Plant Exposed to Pigment-Grade Titanium Dioxide (TiO ₂). <i>Toxics</i> , 2022, 10, 171.	3.7	7
8	miRNA-guided reprogramming of glucose and glutamine metabolism and its impact on cell adhesion/migration during solid tumor progression. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 216.	5.4	11
9	New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4. <i>Molecules</i> , 2022, 27, 1682.	3.8	5
10	A Comprehensive Evaluation of Sdox, a Promising H ₂ S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors. <i>Frontiers in Pharmacology</i> , 2022, 13, 831791.	3.5	3
11	Overcoming Multidrug Resistance (MDR): Design, Biological Evaluation and Molecular Modelling Studies of 2,4-Substituted Quinazoline Derivatives. <i>ChemMedChem</i> , 2022, 17, .	3.2	6
12	Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, , 1.	2.8	1
13	Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 305-322.	3.1	4
14	TFEB controls integrin-mediated endothelial cell adhesion by the regulation of cholesterol metabolism. <i>Angiogenesis</i> , 2022, 25, 471-492.	7.2	10
15	Electronic Coupling in 1,2,3-Triazole Bridged Ferrocenes and Its Impact on Reactive Oxygen Species Generation and Deleterious Activity in Cancer Cells. <i>Inorganic Chemistry</i> , 2022, 61, 9650-9666.	4.0	9
16	Doxorubicin-Loaded Lipid Nanoparticles Coated with Calcium Phosphate as a Potential Tool in Human and Canine Osteosarcoma Therapy. <i>Pharmaceutics</i> , 2022, 14, 1362.	4.5	7
17	Sound-based assembly of a microcapillary network in a saturn-like tumor model for drug testing. <i>Materials Today Bio</i> , 2022, 16, 100357.	5.5	5
18	Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 28.	8.6	72

#	ARTICLE	IF	CITATIONS
19	Joining European Scientific Forces to Face Pandemics. <i>Trends in Microbiology</i> , 2021, 29, 92-97.	7.7	5
20	Identification of Redox-Sensitive Transcription Factors as Markers of Malignant Pleural Mesothelioma. <i>Cancers</i> , 2021, 13, 1138.	3.7	3
21	Predialysis and Dialysis Therapies Differently Affect Nitric Oxide Synthetic Pathway in Red Blood Cells from Uremic Patients: Focus on Peritoneal Dialysis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3049.	4.1	2
22	Plant-Derived Trans- δ^2 -Caryophyllene Boosts Glucose Metabolism and ATP Synthesis in Skeletal Muscle Cells through Cannabinoid Type 2 Receptor Stimulation. <i>Nutrients</i> , 2021, 13, 916.	4.1	8
23	IL17A Depletion Affects the Metabolism of Macrophages Treated with Gemcitabine. <i>Antioxidants</i> , 2021, 10, 422.	5.1	2
24	Efficacy, biocompatibility and degradability of carbon nanoparticles for photothermal therapy of lung cancer. <i>Nanomedicine</i> , 2021, 16, 689-707.	3.3	5
25	miR-141 targeting promotes oxidative stress-dependent cell death. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 136.	8.6	8
26	Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression. <i>Scientific Reports</i> , 2021, 11, 7434.	3.3	3
27	Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. <i>Cancers</i> , 2021, 13, 2332.	3.7	4
28	Targeting Mitochondrial Oncometabolites: A New Approach to Overcome Drug Resistance in Cancer. <i>Pharmaceutics</i> , 2021, 13, 762.	4.5	13
29	HSD17B7 gene in self-renewal and oncogenicity of keratinocytes from Black versus White populations. <i>EMBO Molecular Medicine</i> , 2021, 13, e14133.	6.9	8
30	Targeting HIF-1 α Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL. <i>Cancers</i> , 2021, 13, 2883.	3.7	12
31	Tuning NO release of organelle-targeted furoxan derivatives and their cytotoxicity against lung cancer cells. <i>Bioorganic Chemistry</i> , 2021, 111, 104911.	4.1	8
32	Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies. <i>Cancers</i> , 2021, 13, 2878.	3.7	56
33	The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation. <i>Cell Reports</i> , 2021, 35, 109252.	6.4	29
34	Structure-Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12132-12151.	6.4	34
35	Treatment with ROS detoxifying gold quantum clusters alleviates the functional decline in a mouse model of Friedreich ataxia. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	7
36	Impact of ABC Transporters in Osteosarcoma and Ewing's Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?. <i>Cells</i> , 2021, 10, 2461.	4.1	9

#	ARTICLE	IF	CITATIONS
37	Multifunctional thiosemicarbazones targeting sigma receptors: in vitro and in vivo antitumor activities in pancreatic cancer models. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1307-1323.	4.4	11
38	Overcoming drug resistance in glioblastoma: new options in sight?. , 2021, 4, 512-516.		3
39	Unprecedented collateral sensitivity for cisplatin-resistant lung cancer cells presented by new ruthenium organometallic compounds. <i>Inorganic Chemistry Frontiers</i> , 2021, 8, 1983-1996.	6.0	20
40	Endothelial Heme Dynamics Drive Cancer Cell Metabolism by Shaping the Tumor Microenvironment. <i>Biomedicines</i> , 2021, 9, 1557.	3.2	5
41	Calcium Phosphate-Coated Lipid Nanoparticles as a Potential Tool in Bone Diseases Therapy. <i>Nanomaterials</i> , 2021, 11, 2983.	4.1	9
42	Hypoxia as a driver of resistance to immunotherapy. <i>Drug Resistance Updates</i> , 2021, 59, 100787.	14.4	94
43	Ketogal Safety Profile in Human Primary Colonic Epithelial Cells and in Mice. <i>Pharmaceuticals</i> , 2021, 14, 1149.	3.8	5
44	Endothelial Cells Promote Osteogenesis by Establishing a Functional and Metabolic Coupling With Human Mesenchymal Stem Cells. <i>Frontiers in Physiology</i> , 2021, 12, 813547.	2.8	3
45	Impact of cancer metabolism on therapy resistance – Clinical implications. <i>Drug Resistance Updates</i> , 2021, 59, 100797.	14.4	43
46	Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 80-89.	5.0	14
47	Wnt/IL-1 β /IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5. <i>International Journal of Cancer</i> , 2020, 146, 192-207.	5.1	29
48	From mitochondria to healthy aging: The role of branched-chain amino acids treatment: MATeR a randomized study. <i>Clinical Nutrition</i> , 2020, 39, 2080-2091.	5.0	49
49	Mitochondrial metabolic alterations in cancer cells and related therapeutic targets. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 1-3.	5.0	2
50	HIF-1 α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1042-1054.	3.5	39
51	The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma. <i>Cell Death and Differentiation</i> , 2020, 27, 790-807.	11.2	25
52	Design and synthesis of fluorescent ligands for the detection of cannabinoid type 2 receptor (CB2R). <i>European Journal of Medicinal Chemistry</i> , 2020, 188, 112037.	5.5	14
53	Mutant p53 induces SIRT3/MnSOD axis to moderate ROS production in melanoma cells. <i>Archives of Biochemistry and Biophysics</i> , 2020, 679, 108219.	3.0	18
54	Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets. <i>Drug Resistance Updates</i> , 2020, 49, 100670.	14.4	146

#	ARTICLE	IF	CITATIONS
55	One molecule two goals: A selective P-glycoprotein modulator increases drug transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2020, 208, 112843.	5.5	13
56	Cholesterol metabolism: At the cross road between cancer cells and immune environment. <i>International Journal of Biochemistry and Cell Biology</i> , 2020, 129, 105876.	2.8	28
57	Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance. <i>Cells</i> , 2020, 9, 2598.	4.1	62
58	Synthesis of defined oligohyaluronates-decorated liposomes and interaction with lung cancer cells. <i>Carbohydrate Polymers</i> , 2020, 248, 116798.	10.2	10
59	MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118824.	4.1	11
60	Calcitriol Inhibits Viability and Proliferation in Human Malignant Pleural Mesothelioma Cells. <i>Frontiers in Endocrinology</i> , 2020, 11, 559586.	3.5	11
61	NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma. <i>Cancers</i> , 2020, 12, 3855.	3.7	17
62	Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimer's disease. <i>International Journal of Pharmaceutics</i> , 2020, 591, 120011.	5.2	28
63	MRP1-Collateral Sensitizers as a Novel Therapeutic Approach in Resistant Cancer Therapy: An In Vitro and In Vivo Study in Lung Resistant Tumor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3333.	4.1	15
64	ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma. <i>Cells</i> , 2020, 9, 647.	4.1	30
65	Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4500.	4.1	14
66	Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells. <i>Biomolecules</i> , 2020, 10, 361.	4.0	79
67	Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells. <i>International Journal of Pharmaceutics</i> , 2020, 580, 119191.	5.2	39
68	6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline amides and corresponding ester isosteres as multidrug resistance reversers. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 974-992.	5.2	12
69	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
70	Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death. <i>Cells</i> , 2020, 9, 1033.	4.1	19
71	Overcoming Doxorubicin Resistance with Lipid-Polymer Hybrid Nanoparticles Photoreleasing Nitric Oxide. <i>Molecular Pharmaceutics</i> , 2020, 17, 2135-2144.	4.6	24
72	In vitro vascular toxicity assessment of NitDOX, a novel NO-releasing doxorubicin. <i>European Journal of Pharmacology</i> , 2020, 880, 173164.	3.5	5

#	ARTICLE	IF	CITATIONS
73	Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells. <i>Pharmaceutics</i> , 2020, 12, 96.	4.5	83
74	A regulatory microRNA network controls endothelial cell phenotypic switch during sprouting angiogenesis. <i>ELife</i> , 2020, 9, .	6.0	35
75	Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain Blood Barrier and Glioblastoma Stem Cells. <i>Molecular Pharmaceutics</i> , 2019, 16, 3361-3373.	4.6	14
76	Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111655.	5.5	21
77	Combination of PDT and NOPDT with a Tailored BODIPY Derivative. <i>Antioxidants</i> , 2019, 8, 531.	5.1	10
78	IH2 INHIBITION ENHANCES PROTEASOME INHIBITOR RESPONSIVENESS IN HEMATOLOGICAL MALIGNANCIES. <i>Hematological Oncology</i> , 2019, 37, 515-515.	1.7	0
79	Paracetamol Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug. <i>Molecular Pharmaceutics</i> , 2019, 16, 4181-4189.	4.6	10
80	Sphingolipid Synthesis Inhibition by Myriocin Administration Enhances Lipid Consumption and Ameliorates Lipid Response to Myocardial Ischemia Reperfusion Injury. <i>Frontiers in Physiology</i> , 2019, 10, 986.	2.8	16
81	What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. <i>Drug Resistance Updates</i> , 2019, 46, 100643.	14.4	52
82	New Strategies to Overcome Resistance to Chemotherapy and Immune System in Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4783.	4.1	23
83	Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2226-2231.	7.1	29
84	ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2505.	4.1	98
85	Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1458-1471.	1.1	41
86	Three-Bullets-Loaded Mesoporous Silica Nanoparticles for Combined Photo/Chemotherapy. <i>Nanomaterials</i> , 2019, 9, 823.	4.1	11
87	Fluorescent Nitric Oxide Photodonors Based on BODIPY and Rhodamine Antennae. <i>Chemistry - A European Journal</i> , 2019, 25, 11080-11084.	3.3	26
88	Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. <i>Cancer Letters</i> , 2019, 456, 29-39.	7.2	41
89	Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4174-4192.	6.4	26
90	Methotrexate-Loaded Solid Lipid Nanoparticles: Protein Functionalization to Improve Brain Biodistribution. <i>Pharmaceutics</i> , 2019, 11, 65.	4.5	39

#	ARTICLE	IF	CITATIONS
91	Applicability and Limitations in the Characterization of Poly-Dispersed Engineered Nanomaterials in Cell Media by Dynamic Light Scattering (DLS). <i>Materials</i> , 2019, 12, 3833.	2.9	16
92	Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 974-986.	6.4	26
93	Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 609-625.	5.4	50
94	IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. <i>Blood</i> , 2019, 133, 156-167.	1.4	40
95	Impaired chromaffin cell excitability and exocytosis in autistic Timothy syndrome TS2 mouse rescued by L-type calcium channel blockers. <i>Journal of Physiology</i> , 2019, 597, 1705-1733.	2.9	30
96	Pro- and anti-oxidant properties of near-infrared (NIR) light responsive carbon nanoparticles. <i>Free Radical Biology and Medicine</i> , 2019, 134, 165-176.	2.9	18
97	Nitric Oxide Reinstates Doxorubicin Cytotoxic and Proimmunogenic Effects in Refractory Breast Cancer. , 2019, , 325-326.		0
98	New tetrahydroisoquinoline-based P-glycoprotein modulators: decoration of the biphenyl core gives selective ligands. <i>MedChemComm</i> , 2018, 9, 862-869.	3.4	15
99	New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations. <i>Investigational New Drugs</i> , 2018, 36, 985-998.	2.6	22
100	Tuning the Hydrophobicity of a Mitochondria-Targeted NO Photodonor. <i>ChemMedChem</i> , 2018, 13, 1238-1245.	3.2	9
101	Loss of C/EBP- β LIP drives cisplatin resistance in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2018, 120, 34-45.	2.0	25
102	FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis. <i>Oncogene</i> , 2018, 37, 697-709.	5.9	49
103	Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. <i>OncImmunology</i> , 2018, 7, e1398874.	4.6	41
104	Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (σ_2) receptor and P-gp protein in the cytotoxic action: In vitro and in vivo activity in pancreatic tumors. <i>European Journal of Medicinal Chemistry</i> , 2018, 144, 359-371.	5.5	33
105	Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors. <i>Journal of Controlled Release</i> , 2018, 270, 37-52.	9.9	61
106	A Molecular Hybrid for Mitochondria-Targeted NO Photodelivery. <i>ChemMedChem</i> , 2018, 13, 87-96.	3.2	11
107	1601...Hazard determinants of carbon nanotubes (cnts) driving molecular initiating events (mies) in adverse outcome pathways (aops) of airways diseases. , 2018, , .		0
108	γ T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma. <i>Frontiers in Oncology</i> , 2018, 8, 508.	2.8	15

#	ARTICLE	IF	CITATIONS
109	Increasing intratumor C/EBP- β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 286.	8.6	32
110	Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2018, 1865, 1914-1923.	4.1	45
111	Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2598-2609.	4.1	34
112	An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model <i>in vivo</i> . <i>International Journal of Cancer</i> , 2018, 143, 2065-2075.	5.1	42
113	Metabolic Alterations in a Slow-Paced Model of Pancreatic Cancer-Induced Wasting. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-10.	4.0	19
114	Mitochondrial Delivery of Phenol Substructure Triggers Mitochondrial Depolarization and Apoptosis of Cancer Cells. <i>Frontiers in Pharmacology</i> , 2018, 9, 580.	3.5	22
115	ABCA1, apoA-I, and BTN3A1: A Legitimate M ϕ Age- β Trois in Dendritic Cells. <i>Frontiers in Immunology</i> , 2018, 9, 1246.	4.8	16
116	V β 9V γ 2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression. <i>Frontiers in Immunology</i> , 2018, 9, 1492.	4.8	21
117	New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme <i>In Vitro</i> . <i>Molecules</i> , 2018, 23, 1401.	3.8	13
118	Aceclofenac-Galactose Conjugate: Design, Synthesis, Characterization, and Pharmacological and Toxicological Evaluations. <i>Molecular Pharmaceutics</i> , 2018, 15, 3101-3110.	4.6	12
119	Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 361-365.	2.8	39
120	Rictor/mTORC2 deficiency enhances keratinocyte stress tolerance via mitohormesis. <i>Cell Death and Differentiation</i> , 2017, 24, 731-746.	11.2	24
121	Solid Lipid Nanoparticles Loaded with Antitumor Lipophilic Prodrugs Aimed to Glioblastoma Treatment: Preliminary Studies on Cultured Cells. <i>Journal of Nanoscience and Nanotechnology</i> , 2017, 17, 3606-3614.	0.9	6
122	Solid lipid nanoparticles by coacervation loaded with a methotrexate prodrug: preliminary study for glioma treatment. <i>Nanomedicine</i> , 2017, 12, 639-656.	3.3	28
123	Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?. <i>Future Oncology</i> , 2017, 13, 673-677.	2.4	23
124	PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy. <i>Molecular Cancer</i> , 2017, 16, 91.	19.2	115
125	Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation. <i>European Journal of Medicinal Chemistry</i> , 2017, 141, 703-720.	5.5	36
126	Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. <i>Journal of Hematology and Oncology</i> , 2017, 10, 16.	17.0	101

#	ARTICLE	IF	CITATIONS
127	The ATP-binding cassette transporter A1 regulates phosphoantigen release and $\hat{V}^{39}\hat{V}^{2}$ T cell activation by dendritic cells. <i>Nature Communications</i> , 2017, 8, 15663.	12.8	57
128	$\hat{I}\%{-}3$ Long Chain Polyunsaturated Fatty Acids as Sensitizing Agents and Multidrug Resistance Revertants in Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2770.	4.1	44
129	Endogenous glutamine decrease is associated with pancreatic cancer progression. <i>Oncotarget</i> , 2017, 8, 95361-95376.	1.8	41
130	Comparison of Allogeneic and Syngeneic Rat Glioma Models by Using MRI and Histopathologic Evaluation. <i>Comparative Medicine</i> , 2017, 67, 147-156.	1.0	6
131	P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors. <i>Oncotarget</i> , 2016, 7, 85861-85875.	1.8	34
132	Nitric oxide synthetic pathway and cGMP levels are altered in red blood cells from end-stage renal disease patients. <i>Molecular and Cellular Biochemistry</i> , 2016, 417, 155-167.	3.1	16
133	H ₂ S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4881-4889.	6.4	43
134	Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2640-2652.	4.1	82
135	Development of sigma-1 ($\hat{I}f 1$) receptor fluorescent ligands as versatile tools to study $\hat{I}f 1$ receptors. <i>European Journal of Medicinal Chemistry</i> , 2016, 108, 577-585.	5.5	11
136	Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 967-975.	3.0	24
137	Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest. <i>Oncotarget</i> , 2016, 7, 5598-5612.	1.8	118
138	Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. <i>Oncotarget</i> , 2016, 7, 20753-20772.	1.8	39
139	ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and $\hat{V}^{39}\hat{V}^{2}$ T-Cell Activation By Dendritic Cells. <i>Blood</i> , 2016, 128, 3709-3709.	1.4	0
140	HIF-1 $\hat{I}\pm$ Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. <i>Blood</i> , 2016, 128, 305-305.	1.4	0
141	Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance. <i>Blood</i> , 2016, 128, 3210-3210.	1.4	0
142	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 588.	4.8	317
143	Editorial: Multidrug Resistance in Cancer: Pharmacological Strategies from Basic Research to Clinical Issues. <i>Frontiers in Oncology</i> , 2015, 5, 105.	2.8	21
144	Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells. <i>Oncotarget</i> , 2015, 6, 31461-31478.	1.8	40

#	ARTICLE	IF	CITATIONS
145	Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. <i>Oncotarget</i> , 2015, 6, 6776-6793.	1.8	102
146	Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary <i>in vitro</i> studies. <i>Nanotechnology</i> , 2015, 26, 255102.	2.6	65
147	Mitochondrial Targeting of Doxorubicin Eliminates Nuclear Effects Associated with Cardiotoxicity. <i>ACS Chemical Biology</i> , 2015, 10, 2007-2015.	3.4	64
148	Novel and Selective Fluorescent β -Receptor Ligand with a 3,4-Dihydroisoquinolinone Scaffold: A Tool to Study β Receptors in Living Cells. <i>ChemBioChem</i> , 2015, 16, 1078-1083.	2.6	23
149	Mouse hepatocytes and LSEC proteome reveal novel mechanisms of ischemia/reperfusion damage and protection by A2aR stimulation. <i>Journal of Hepatology</i> , 2015, 62, 573-580.	3.7	30
150	Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein. <i>Cancer Letters</i> , 2015, 360, 219-226.	7.2	49
151	The Role of C/EBP- β LIP in Multidrug Resistance. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	39
152	The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment. <i>International Journal of Oncology</i> , 2015, 46, 2299-2308.	3.3	44
153	Anergic bone marrow $\gamma\delta$ T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. <i>Oncolmmunology</i> , 2015, 4, e1047580.	4.6	58
154	An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0126159.	2.5	27
155	Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma. <i>Oncotarget</i> , 2015, 6, 1128-1142.	1.8	32
156	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. <i>Oncotarget</i> , 2015, 6, 29833-29846.	1.8	33
157	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. <i>Blood</i> , 2015, 126, 2925-2925.	1.4	0
158	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	4.6	686
159	Rho-GTPases and Statins: A Potential Target and a Potential Therapeutic Tool Against Tumors?. , 2014, , 209-245.		0
160	Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3 signaling. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 499-516.	5.4	46
161	Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 77-87.	3.3	36
162	The Cross-Talk between Canonical and Non-Canonical Wnt-Dependent Pathways Regulates P-Glycoprotein Expression in Human Blood-Brain Barrier Cells. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1258-1269.	4.3	49

#	ARTICLE	IF	CITATIONS
163	Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 88, 746-758.	4.3	68
164	Solid Lipid Nanoparticles for Potential Doxorubicin Delivery in Glioblastoma Treatment: Preliminary In Vitro Studies. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 2157-2165.	3.3	77
165	Novel Derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with Improved Fluorescent and If Receptors Binding Properties. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 3314-3323.	6.4	18
166	Liposomal Nitrooxy-Doxorubicin: One Step over Caelyx in Drug-Resistant Human Cancer Cells. <i>Molecular Pharmaceutics</i> , 2014, 11, 3068-3079.	4.6	29
167	A diabetic milieu promotes OCT4 and NANOG production in human visceral-derived adipose stem cells. <i>Diabetologia</i> , 2013, 56, 173-184.	6.3	37
168	Doxorubicin-antioxidant co-drugs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5307-5310.	2.2	27
169	Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/Ā-catenin pathway. <i>Neuro-Oncology</i> , 2013, 15, 1502-1517.	1.2	64
170	Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. <i>Molecular Cancer</i> , 2013, 12, 137.	19.2	84
171	Mitochondrial-Targeting Nitrooxy-doxorubicin: A New Approach To Overcome Drug Resistance. <i>Molecular Pharmaceutics</i> , 2013, 10, 161-174.	4.6	62
172	Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells. <i>Oncolmmunology</i> , 2013, 2, e25770.	4.6	20
173	Nanoparticle- and Liposome-carried Drugs: New Strategies for Active Targeting and Drug Delivery Across Blood-brain Barrier. <i>Current Drug Metabolism</i> , 2013, 14, 625-640.	1.2	70
174	Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e60975.	2.5	49
175	Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes. <i>Biochemical Journal</i> , 2012, 447, 301-311.	3.7	27
176	Dysfunctional Vĳ3Vĳ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. <i>Blood</i> , 2012, 120, 3271-3279.	1.4	51
177	The pentose phosphate pathway: An antioxidant defense and a crossroad in tumor cell fate. <i>Free Radical Biology and Medicine</i> , 2012, 53, 421-436.	2.9	334
178	The association of statins plus LDL receptorĀ-targeted liposomeĀ-encapsulated doxorubicin increases <i>in vitro</i> drug delivery across bloodĀ-brain barrier cells. <i>British Journal of Pharmacology</i> , 2012, 167, 1431-1447.	5.4	71
179	HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. <i>BMC Cancer</i> , 2012, 12, 4.	2.6	142
180	Human ĩĳTĳ cell responses in infection and immunotherapy: Common mechanisms, common mediators?. <i>European Journal of Immunology</i> , 2012, 42, 1668-1676.	2.9	53

#	ARTICLE	IF	CITATIONS
181	Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. <i>Biochemical Journal</i> , 2011, 439, 141-149.	3.7	63
182	Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 494-497.	2.8	63
183	Liposome-Encapsulated Doxorubicin Reverses Drug Resistance by Inhibiting P-Glycoprotein in Human Cancer Cells. <i>Molecular Pharmaceutics</i> , 2011, 8, 683-700.	4.6	93
184	IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. <i>Leukemia</i> , 2011, 25, 828-837.	7.2	61
185	Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 1492-1504.	3.6	28
186	A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells. <i>Journal of Controlled Release</i> , 2011, 149, 196-205.	9.9	57
187	Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer. <i>Biochemical Pharmacology</i> , 2011, 82, 1079-1089.	4.4	12
188	Pleiotropic Effects of Cardioactive Glycosides. <i>Current Medicinal Chemistry</i> , 2011, 18, 872-885.	2.4	64
189	Antioxidants Prevent the RhoA Inhibition Evoked by Crocidolite Asbestos in Human Mesothelial and Mesothelioma Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 625-631.	2.9	12
190	Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between $\text{V}\beta 9\text{V}\beta 2$ T Cells, $\text{I}\beta 2$ CD8 ⁺ T Cells, Regulatory T Cells, and Dendritic Cells. <i>Journal of Immunology</i> , 2011, 187, 1578-1590.	0.8	77
191	Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2803-2815.	3.6	228
192	Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process. <i>Cancer Research</i> , 2010, 70, 10329-10339.	0.9	92
193	High aspect ratio materials: role of surface chemistry vs. length in the historical $\text{H}\beta$ and short amosite asbestos fibers. <i>Inhalation Toxicology</i> , 2010, 22, 984-998.	1.6	40
194	Fluoride Effects: The Two Faces of Janus. <i>Current Medicinal Chemistry</i> , 2010, 17, 2431-2441.	2.4	90
195	Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1 β in human colon cancer cells. <i>Toxicology and Applied Pharmacology</i> , 2009, 240, 385-392.	2.8	32
196	Digoxin and ouabain increase the synthesis of cholesterol in human liver cells. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 1580-1594.	5.4	27
197	Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1 β and P-glycoprotein overexpression. <i>British Journal of Pharmacology</i> , 2009, 156, 1054-1066.	5.4	111
198	Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis. <i>British Journal of Pharmacology</i> , 2009, 158, 1777-1786.	5.4	48

#	ARTICLE	IF	CITATIONS
199	iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. <i>Molecular Cancer</i> , 2009, 8, 108.	19.2	70
200	The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. <i>Blood</i> , 2009, 113, 2776-2790.	1.4	42
201	The NADPH oxidase inhibitor apocynin induces nitric oxide synthesis via oxidative stress. <i>Toxicology and Applied Pharmacology</i> , 2008, 228, 277-285.	2.8	38
202	Activation of Nuclear Factor- κ B Pathway by Simvastatin and RhoA Silencing Increases Doxorubicin Cytotoxicity in Human Colon Cancer HT29 Cells. <i>Molecular Pharmacology</i> , 2008, 74, 476-484.	2.3	63
203	RhoA Silencing Reverts the Resistance to Doxorubicin in Human Colon Cancer Cells. <i>Molecular Cancer Research</i> , 2008, 6, 1607-1620.	3.4	50
204	Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific. <i>Current Drug Metabolism</i> , 2008, 9, 686-696.	1.2	182
205	Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1 α . <i>European Respiratory Journal</i> , 2008, 32, 443-451.	6.7	20
206	Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy. <i>Mini-Reviews in Medicinal Chemistry</i> , 2008, 8, 609-618.	2.4	15
207	Asbestos Induces Nitric Oxide Synthesis in Mesothelioma Cells via Rho Signaling Inhibition. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2007, 36, 746-756.	2.9	7
208	Iron-Loaded Synthetic Chrysotile: A New Model Solid for Studying the Role of Iron in Asbestos Toxicity. <i>Chemical Research in Toxicology</i> , 2007, 20, 380-387.	3.3	81
209	Cycling of NADPH by glucose 6-phosphate dehydrogenase optimizes the spectrophotometric assay of nitric oxide synthase activity in cell lysates. <i>Nitric Oxide - Biology and Chemistry</i> , 2006, 15, 148-153.	2.7	28
210	Insulin activates hypoxia-inducible factor-1 α in human and rat vascular smooth muscle cells via phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways: impairment in insulin resistance owing to defects in insulin signalling. <i>Diabetologia</i> , 2006, 49, 1049-1063.	6.3	47
211	The NADPH oxidase inhibitor apocynin (acetovanillone) induces oxidative stress. <i>Toxicology and Applied Pharmacology</i> , 2006, 212, 179-187.	2.8	73
212	Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma. <i>International Journal of Cancer</i> , 2006, 119, 17-27.	5.1	58
213	Different cellular responses evoked by natural and stoichiometric synthetic chrysotile asbestos. <i>Toxicology and Applied Pharmacology</i> , 2005, 206, 356-364.	2.8	50
214	Na ⁺ /H ⁺ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. <i>International Journal of Cancer</i> , 2005, 115, 924-929.	5.1	75
215	POTENTIAL TOXICITY OF NONREGULATED ASBESTIFORM MINERALS: BALANGEROITE FROM THE WESTERN ALPS. PART 3: DEPLETION OF ANTIOXIDANT DEFENSES. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2005, 68, 41-49.	2.3	34
216	POTENTIAL TOXICITY OF NONREGULATED ASBESTIFORM MINERALS: BALANGEROITE FROM THE WESTERN ALPS. PART 2: OXIDANT ACTIVITY OF THE FIBERS. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2005, 68, 21-39.	2.3	28

#	ARTICLE	IF	CITATIONS
217	Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. <i>Cancer Research</i> , 2005, 65, 516-25.	0.9	187
218	Diphenyleneiodonium Inhibits the Cell Redox Metabolism and Induces Oxidative Stress. <i>Journal of Biological Chemistry</i> , 2004, 279, 47726-47731.	3.4	169
219	Simian Virus 40 Infection Down-Regulates the Expression of Nitric Oxide Synthase in Human Mesothelial Cells. <i>Cancer Research</i> , 2004, 64, 4082-4084.	0.9	13
220	Nitroarginine methyl ester and canavanine lower intracellular reduced glutathione. <i>Free Radical Biology and Medicine</i> , 2003, 35, 1210-1216.	2.9	7
221	Long and short fiber amosite asbestos alters at a different extent the redox metabolism in human lung epithelial cells. <i>Toxicology and Applied Pharmacology</i> , 2003, 193, 106-115.	2.8	39
222	Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF- κ B activation. <i>FEBS Letters</i> , 2003, 552, 141-144.	2.8	135
223	Insulin Stimulates Glucose Transport Via Nitric Oxide/Cyclic GMP Pathway in Human Vascular Smooth Muscle Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 2215-2221.	2.4	86
224	Crocidolite asbestos inhibits pentose phosphate oxidative pathway and glucose 6-phosphate dehydrogenase activity in human lung epithelial cells. <i>Free Radical Biology and Medicine</i> , 2002, 32, 938-949.	2.9	59
225	Doxorubicin Induces an Increase of Nitric Oxide Synthesis in Rat Cardiac Cells That Is Inhibited by Iron Supplementation. <i>Toxicology and Applied Pharmacology</i> , 2002, 185, 85-90.	2.8	55
226	Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	11